Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 21, 2026
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: October 16, 2024
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.
Journal: International journal of radiation oncology, biology, physics
Published: March 28, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: August 07, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 09, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Journal: JAMA oncology
Published: September 29, 2022
Cervical cancer patient reported gastrointestinal outcomes: intensity/volumetric modulated vs. 3D conformal radiation therapy.
Journal: Journal of gynecologic oncology
Published: September 23, 2021
A population-based study examining the influence of a specialized rapid-access cancer clinic on initial treatment choice in localized prostate cancer.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: April 01, 2018
Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health.
Journal: Acta oncologica (Stockholm, Sweden)
Published: January 24, 2018
Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.
Journal: Neurosurgery
Published: March 11, 2017
Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Journal: International journal of radiation oncology, biology, physics
Published: July 21, 2016
Last Updated: 09/26/2026